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Abstract
Background: Celiac disease (CD) occurs in as many as 1 in 80 pregnant women and is associated
with poor pregnancy outcome, but it is not known if this is an effect on maternal nutrient
absorption or, alternatively, if the placenta is an autoimmune target. The major autoantigen, tissue
transglutaminase (tTG), has previously been shown to be present in the maternal-facing
syncytiotrophoblast plasma membrane of the placenta.
Methods: ELISA was used to demonstrate the presence of antibodies to tissue transglutaminase
in a panel of CD sera. Immunohistochemistry was used to evaluate the binding of IgA
autoantibodies from CD serum to term placenta. In addition, novel direct binding and activity
assays were developed to mimic the in vivo exposure of the villous placenta to maternal
autoantibody.
Results and Discussion: CD IgA autoantibodies located to the syncytial surface of the placenta
significantly more than IgA antibodies in control sera (P < 0.0001). The distribution of antigen was
similar to that observed using a monoclonal antibody to tissue transglutaminase. Staining was
reduced by pre-absorption of CD serum with recombinant human tissue transglutaminase. In direct
binding assays, autoimmune immunoglobulin A (IgA) from the maternal compartment became
associated with antigen at the syncytial surface of the placenta, as a result of which transglutaminase
activity at this site was inhibited.
Conclusion: These data indicate that direct immune effects in untreated CD women may
compromise placental function.
Background
Celiac disease (CD) is caused by intolerance to dietary glu-
ten, resulting in immunologically-mediated inflamma-
tory damage of the small intestinal mucosa,
malabsorption and nutritional deficiency[1,2]. The
enzyme tissue transglutaminase (tTG) has been identified
as the major autoantigen in CD[3]. tTG is a multifunc-
tional protein that catalyses the formation of cross-links
between proteins, has GTPase activity associated with G-
protein-linked signalling[4] as well as being a kinase[5].
tTG is widely expressed in tissues, where it is often found
associated with cell membranes[1,6]. Its functions appear
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by in vivo data suggests that tTG is important in the regu-
lation of late events in apoptosis, when cellular remnants
are stabilized by cross-linking in preparation for disposal
in the absence of inflammatory stimuli[7].
With the wide availability of sensitive serological screen-
ing tests that detect anti-endomysial (EMA) and anti-tTG
antibodies, it has become apparent that the prevalence of
CD is higher than had been previously suspected [8-11].
Many, if not most, cases have either a clinically silent form
of the disease, or only a minor enteropathy[12,13].
Untreated celiac disease has been associated with poor
pregnancy outcomes including higher rates of infertility,
recurrent miscarriage, intrauterine growth restriction
(IUGR), and stillbirth [14-20]. IUGR, perhaps the most
predictable potential outcome of impaired maternal
nutrient absorption, is an important cause of perinatal
morbidity and mortality as well as giving rise to increased
risk of poor health in adult life[21,22]. A 9-fold increased
incidence of IUGR has been reported in CD[23] with
equivalent effects in women with subclinical disease and
an estimated 1 in 80 pregnancies may be affected by CD.
This incidence is comparable to the incidence of diabetes
[24] and thyroid disease [25]. Studies to characterize CD
pregnancies are constrained by the likelihood that trans-
ferring affected women to a gluten-free diet (GFD) would
improve outcome. Therefore, data on placental develop-
ment and fetal growth in CD are scant and the mecha-
nisms by which pregnancy may be affected are not
established.
In order to develop an evidence base from which to judge
whether routine CD screening should be instituted in
pregnant women, there is a pressing need for in vitro
approaches to understand mechanisms of pregnancy
impairment. A central question is whether maternal mal-
absorption may be complicated by direct immune attack
on the placenta. Functionally active tTG is present at the
syncytiotrophoblast microvillous membrane (MVM) [26-
28], where a group of substrate proteins has been identi-
fied[28]. The MVM is the primary exchange interface
between maternal and fetal tissues and is perfused directly
by maternal blood. We have suggested a role for tTG in
trophoblast apoptosis and shedding from this sur-
face[28]. In the present study we use novel binding and
function assays to show that CD-derived IgA binds tTG at
the maternal surface of the placenta and inhibits its func-
tion. The results suggest that CD placentas may carry a
high autoimmune immunoglobulin load, leading to
developmental or functional impairment.
Methods
Serum and EMA assay
Anti-endomysium antibodies (EMA) were determined by
indirect immunofluorescence on pig intestine. 132 serum
samples from non-pregnant donors were provided by the
immunology laboratory of the Manchester Royal Infir-
mary and stored at -20°C. EMA-positive sera were reas-
sayed blind at 1:30, 1:100, 1:300 and 1:1000.
tTG assay
A commercial ELISA (Celikey; Pharmacia Diagnostics)
was used to determine anti-tTG IgA levels in patient sera.
Results are reported as positive (OD ratio >1.4), border-
line (OoralD ratio 1–1.4) and negative (OD ratio <1). The
presence of tTG reactive IgA was confirmed by western
blotting (not shown).
Immunohistochemistry
Sections of normal term placenta were dewaxed and incu-
bated in methanol containing 0.15% hydrogen peroxide
for 30 min to quench endogenous peroxidase activity,
then microwaved in 0.01 M sodium citrate buffer pH 6.0,
10 min to achieve antigen recovery. Sections were incu-
bated with protein block for 30 min then with autoim-
mune serum (tTG-positive or -negative; 1:10) overnight at
4°C. Mouse monoclonal anti-tTG (CUB 7402; 1:100,
Labvision) was used as a positive control[26].
Sections were rinsed in TBS (x3) then incubated with
either goat anti-mouse immunoglobulin-HRP or rabbit
anti-human IgA-HRP (1:40, 30 min; Dako P0447 and
P0216 respectively). After washing, sections were incu-
bated with avidin-peroxidase (5 μg/ml in 0.125 M TBS, 1
h), developed in 3, 3' diaminobenzidine tetrahydrochlo-
ride (DAB) (10 mg/ml DAB/TBS, 0.0045% hydrogen per-
oxide) for 3 min, then nuclei counterstained with 0.25%
methyl green.
The stained area (for syncytioplasm) or the linear staining
(for the syncytial microvillous membrane) was obtained
from a set of 20–25 serial images. Significance of differ-
ence between control and autoimmune staining were esti-
mated using the Mann-Whitney test. Staining intensity
was graded in a range + (weak) to +++ (intense).
Pre-absorption study: blockade of immunoperoxidase 
staining of human term placental tissue with human 
recombinant tTg
Serum positive for anti tTG antibodies (1:20 dilution in
PBS) or mouse monoclonal anti-tTG (CUB 7204) at 1:400
dilution was incubated with recombinant human tTG
(rhtTG) in different concentrations (5 μg, 2.5 μg, 1.25 μg)
at 37°C for two hours prior to incubation with wax sec-
tions as described earlier.Page 2 of 7
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7402 (1:400 dilution) and PBS were used as positive and
negative controls respectively. Goat anti mouse-HRP or
rabbit anti human IgA-HRP were used in 1:40 dilutions as
secondary antibodies. Controls were also carried out in
which serum (1:20) or monoclonal anti-tTG were prein-
cubated with recombinant human tTG (2.5 μg, 37°C 2 h)
prior to staining. Full inhibition was achieved in both
instances.
Direct binding of IgA to the placental villus
Placental tissue was fine-dissected to produce 2–3 mm
pieces with intact villous architecture including stem,
intermediate and terminal branches, fixed in 4% PFA/PBS
for 2 h, then washed in 1% BSA/PBS (4 × 30 min). Positive
or negative serum (1:10 in 5% BSA/PBS) and mouse mon-
oclonal anti-tTG (1:200 in 5% BSA/PBS) were used as pri-
mary antibodies. Rabbit anti-human IgA-FITC (1:40;
Dako F0204) and rabbit anti-mouse IgG-FITC (1:40;
Dako F0261) secondary antibodies were used. The speci-
mens were incubated with primary and secondary anti-
bodies, washed in PBS (×4) in foil-wrapped eppendorf
tubes over 30 min on a roller-mixer, snap frozen in OCT
and cryosectioned. Negative controls contained either no
primary antibody or anti-β-actin antibody (1:5000 in 5%
BSA/PBS). The actin antibody produced staining only in
the immediate vicinity (within ~50 μm) of cut surfaces
(not shown), proving that fully epithelialised placental
tissue was neither permeable to immunoglobulin nor
leaky.
In situ tTG activity and its inhibition by autoantibody
Syncytial tTG activity was assayed in situ by the incorpora-
tion of a fluorescent substrate into target proteins at the
surface of intact placental tissue. Tissue (2–3 mm pieces)
was incubated with the acyl donor hexapeptide biotinyl-
TVQQEL[28,29] (0.5 mM in serum-free F12/DMEM, 37°,
30 min). After the reaction, specimens were washed in
F12/DMEM (2 × 2 min), fixed in 4% PFA (30 min),
washed again (4 × 30 min), snap frozen in OCT and cryo-
sectioned. Sections were incubated with streptavidin-FITC
(1:200), washed and mounted using Vectashield contain-
ing propidium iodide. For the tTG activity inhibition
assay, placental tissue pieces were directly incubated with
serum (1:20 in 5% BSA/PBS) or monoclonal anti-tTG
antibody (1:200) prior to addition of the acyl donor sub-
strate.
Results
Autoimmune IgA binds to the placenta
The EMA tissue immunofluorescence test for CD may
detect autoantibody to non-tTG targets. 132 serum sam-
ples from a general immunology clinic were therefore
tested for EMA and then assayed blind for tTG antibodies
(table 1). All sera positive for EMA at 1:1000 also con-
tained anti-tTG reactivity and 60/74 (81%) of sera nega-
tive for EMA were also negative for anti-tTG. 14/74
(18.9%) of EMA-negatives were positive for anti-tTG
while 13/58 (22.4%) of EMA-positives (all dilutions)
were negative for the anti-tTG assay. Seven of twelve sera
that were strongly positive in both assays were of suffi-
cient volume for further experiments. Seven negative sera
were selected as controls.
Sera were used for immunohistochemistry of term placen-
tal tissue. Monoclonal anti-tTG stained strongly the syncy-
tial microvillous membrane (MVM) as well as
cytotrophoblast and stromal and vascular elements, con-
firming previous data (figure 1A) [26,27]. IgA could not
be detected in control sections stained either with anti-
human IgA secondary only (not shown) or anti-tTG-neg-
ative serum (figure 1C). All tTG-positive sera contained
IgA that recognised target antigen in both cytotrophoblast
and syncytial MVM (table 2) as well as endothelial and
decidual cells (not shown). The intensity of staining in the
MVM was variable, suggesting a non-uniform distribution
over the surface of the villus (figure 1A). Antibody bind-
ing was inhibited by pre-incubation of serum with recom-
binant human tTG (figure 1B). Two tTG-negative sera
showed weak reactivity with cytotrophoblast and syncy-
Table 1: Correlation of anti tTG immunoassay (ELISA) with EMA assays.


































Total 74 6 21 19 12
Number of serum samples are given with and percentages in parentheses. Samples positive for EMA were tested in serial dilutions (1 in 30, 1 in 100, 
1 in 300 and 1 in 1000). Anti tTG antibody results are reported as positive (OD ratio >1.4), borderline (OD ratio 1–1.4) and negative (OD ratio 
<1).Page 3 of 7
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gets in the placenta (table 2).
IgA can be recruited to the placental surface from the 
intervilllous space
Immunohistochemistry demonstrated binding at the
MVM, but the resolution of the technique is insufficient to
distinguish tTG at the outer or inner surface. A direct bind-
ing assay was developed to investigate whether maternal
IgA circulating in the intervillous space could interact
directly with target tTG on the outer surface of the pla-
centa. Small pieces of villous tissue were fixed under non-
permeabilising conditions, then incubated in autoim-
mune serum and bound IgA localised by fluorescence
microscopy after sectioning. Abundant antigen could be
detected at the surface of the placenta (figures 2A,B).
When anti-tTG-negative serum was used, no staining was
observed (figure 2C). These experiments indicate that tTG
at the MVM is accessible to antibody binding from mater-
nal circulation.
tTG activity in the MVM is inhibited by autoantibody
Given the presence of accessible, immunoreactive tTG, a
method was developed to detect tTG enzymatic activity in
the MVM. Small pieces of villous tissue were dissected
from term placenta obtained within 30 min of delivery
and incubated in a biotinylated acyl donor substrate pep-
tide. Cryosections were produced and stained with fluo-
rescent avidin in order to reveal sites of activity. The
results (figure 3) indicate substrate localised to the MVM,
showing that enzyme is accessible to small substrates and
is active in situ. When placental tissue was preincubated
with monoclonal anti-tTG or with anti-tTG-positive
serum before adding substrate, biotinylation was strongly
inhibited (figure 3) demonstrating the ability of CD
autoantibodies to alter the activity of tTG in the placental
MVM.
Discussion
In previous studies we used immunohistochemistry of
placental tissue sections to establish that tTG is widely
expressed, and biochemical assays to show active tTG in
the MVM[26,28]. The results now reported show that CD
sera contain IgA that binds to tTG in the same placental
sites. However the placenta is an effective immunological
barrier, and in order to establish in principle that placen-
tal autoantigen may be accessible to the maternal immune
system, it was necessary to devise a direct binding assay
using intact villous tissue. The data obtained prove une-
quivocally that placental tTG is accessible to binding of
maternal autoantibody, suggesting that it is associated
with the outer face of the MVM. Using in situ enzymology
we have shown that the enzyme is active at this site and is
inhibited both by monospecific anti-tTG antibody and by
CD sera.
The results indicate the likelihood that placental tTG
activity is impaired in CD pregnancies. The consequences
for function are not yet clear but as the major site of nutri-
ent exchange, the MVM is vulnerable to pathogenic effects
that may impair membrane-associated processes includ-
ing nutrient import. Altered apoptosis has been reported
in CD placentas[30]. We have postulated [28] that tTG
plays a role in stabilizing fragments shed from the syncy-
tiotrophoblast microvillous membrane into maternal cir-
culation. Particle cross-linking may stabilise the
constituent supramolecular complexes which may there-
fore be more efficiently phagocytosed. Inhibition of cross-
linking by autoantibody may cause destabilization of the
particulate fraction with consequent release of soluble
fetoplacental antigen and exposure of the maternal
immune system to an altered immunological challenge
from the hemiallogeneic placenta. In turn this may have
wider systemic consequences for immune recognition of
the conceptus. These ideas will require experimental vali-
dation, but in the meantime the data presented add sup-
port to the case for screening for CD in early pregnancy
with the intent to offer a gluten-free diet to anti-tTG anti-
body-positive women.
Abbreviations
(OD): Absorbance; (anti tTG antibody): Anti tissue trans-
glutaminase antibody; (EMA): Endomysium antibodies;
(Av PO): Avidin peroxidase; (CD): Coeliac disease;
Table 2: Immunostaining of human term placenta using anti-tTG-positive or -negative sera.




Apical syncytial MVM 7/7 2/7 (the other 5 were negative)
Linear proportion stained 22–48% 15–25% **p = 0.0001
Grading of staining ++/+++ +/++
Syncytioplasm 7/7 2/7
Area stained 17–68% 15–25% **p = 0.0001
Grading of staining +++/++ +/++
Data are given as linear proportion stained (MVM) or area stained (syncytioplasm) with an associated intensity range.Page 4 of 7
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A) Immunohistochemical staining (brown with blue hematoxylin counterstain) showing IgA from CD serum binding at the syn-cytial (maternal) surface of term placenta; B) binding is abolished by pr incubation of serum with recombinant tissue rans-glut min s ; C) negativ cont ol serum fails o stainFigure 1
A) Immunohistochemical staining (brown with blue hematoxylin counterstain) showing IgA from CD serum 
binding at the syncytial (maternal) surface of term placenta; B) binding is abolished by preincubation of serum 





Reproductive Biology and Endocrinology 2009, 7:16 http://www.rbej.com/content/7/1/16
Page 6 of 7
(page number not for citation purposes)
A novel direct binding assayFigur  2
A novel direct binding assay. Sera positive or negative for 
anti-tTG antibody were directly incubated with intact placen-
tal villous tissue fragments and followed by FITC-conjugated 
anti-IgA. Tissue was then cryosectioned and counterstained 
for nuclei (PI; red). A) Positive control: mouse monoclonal 
anti tTG; B) serum positive for anti tTG; C) serum negative 
for anti-tTG. The green staining on the outer surface of the 




CD serum inhibits tTG enzymatic activity at the surface of the placentaFigure 3
CD serum inhibits tTG enzymatic activity at the sur-
face of the placenta. Villous tissue was incubated of with 
an acyl donor tTG substrate (biotinyl-TVQQEL), then biotin 
incorporation visualised by staining with a green fluorescent 
avidin conjugate. A) Staining in trophoblast, indicating incor-
poration of the substrate. This was completely abolished 
after tissue had been pre-treated with B) mouse monoclonal 
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